ORAMED PHARMACEUTICALS INC. 3
3 · Lifeward Ltd. · Filed May 14, 2026
Insider Transaction Report
Form 3
Lifeward Ltd.LFWD
ORAMED PHARMACEUTICALS INC.
10% Owner
Holdings
- 1,250,363
Ordinary Shares
Warrants (right to buy)
[F1][F2]Exercise: $0.00→ Ordinary Shares (1,006,113 underlying)Warrants (right to buy)
[F3]Exercise: $5.40Exp: 2031-03-25→ Ordinary Shares (1,296,296 underlying)Warrants (right to buy)
[F4]Exercise: $5.40Exp: 2031-03-25→ Ordinary Shares (1,666,666 underlying)Senior Secured Convertible Notes
[F5][F6]Exercise: $5.40→ Ordinary Shares (1,666,666 underlying)
Footnotes (6)
- [F1]Pursuant to the terms of the pre-funded warrants (the "Pre-Funded Warrants"), Lifeward Inc. (the "Issuer") may not effect any exercise of the Pre-Funded Warrants, and Oramed Pharmaceuticals Inc. (the "Reporting Person") may not exercise the Pre-Funded Warrants, to the extent that after giving effect to such issuance after exercise, the Reporting Person would beneficially own more than 49.99% of the outstanding ordinary shares, no par value ("Ordinary Shares") of the Issuer (the "49.99% Beneficial Ownership Limitation").
- [F2]Subject to the 49.99% Beneficial Ownership Limitation, the Pre-Funded Warrants are freely exercisable.
- [F3]Pursuant to the terms of the share purchase warrants (the "Share Purchase Warrants"), the Issuer may not effect any exercise of the Share Purchase Warrants, and the Reporting Person may not exercise the Share Purchase Warrants, to the extent that after giving effect to such issuance after exercise, the Reporting Person would beneficially own more than 49.99% of the Ordinary Shares.
- [F4]Pursuant to the terms of the purchase agreement warrants (the "Purchase Agreement Warrants"), the Issuer may not effect any exercise of the Purchase Agreement Warrants, and the Reporting Person may not exercise the Purchase Agreement Warrants, to the extent that after giving effect to such issuance after exercise, the Reporting Person would beneficially own more than 45.0% of the Ordinary Shares.
- [F5]Pursuant to the terms of the senior secured convertible notes (the "Notes"), the Issuer may not effect any conversion of the Notes, and the Reporting Person may not convert the Notes, to the extent that after giving effect to such issuance after conversion, the Reporting Person would beneficially own more than 45.0% of the Ordinary Shares (the "45% Beneficial Ownership Limitation").
- [F6]Subject to the 45% Beneficial Ownership Limitation, the Notes are freely convertible.
Signature
By: /s/ Avraham Gabay Name: Avraham Gabay Title: Chief Financial Officer|2026-05-14